Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences
Healthcare ServicesKey Fundamentals
SmallcapHospitalsHealthcare ServicesTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is expected to give good quarter
- Company's median sales growth is 21.9% of last 10 years
Weaknesses
4- Stock is trading at 13.1 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.62%
- Company might be capitalizing the interest cost
Growth Rate
AI Analysis — Bull vs Bear
KIMS has a market capitalisation of about Rs 33,233 crore and trades at a P/E of 172.9 and a P/B of 8.97; the provided cons list cites 13.9x book value, so the two sources disagree. Revenue growth is strong, with TTM sales up 31% and 10-year sales CAGR at 23%. Profit has moved the other way: TTM profit is down 43%, 3-year profit CAGR is -9%, and ROE has fallen to 11% last year from a 5-year average of 18%.
- Top-line growth is speeding up. TTM sales growth of 31% is above the 3-year CAGR of 21%, which suggests new or expanded capacity is starting to bring in revenue.
- Revenue growth has held up over a long period: 10-year sales CAGR of 23%, 5-year of 24%, and median sales growth of 21.9% over the last 10 years.
- Over the long run, profit has grown in step with sales, with a 10-year compounded profit CAGR of 25%. The recent decline breaks a long-term growth pattern.
- Return on equity has historically been healthy for a hospital business, averaging 18% over both 5 and 10 years. That points to what mature hospitals can earn once they ramp up.
- Shareholders have seen 26% stock CAGR over both 3 and 5 years, reflecting sustained market confidence in the growth story.
- The company is expected to report a good quarter. If profit recovers, the TTM profit decline of -43% could reverse and bring the P/E of 172.9 down quickly.
- The company pays no dividend (0% yield) and keeps all its cash. That supports reinvestment in a sector where new beds and hospitals drive future revenue, as the 31% TTM sales growth shows.
- The valuation is very high. A P/E of 172.9 comes alongside a TTM profit decline of -43%, so the stock is priced for a sharp earnings recovery that has not happened yet.
- Earnings are going backwards even as sales grow. 3-year compounded profit growth is -9% against 21% sales growth, which points to shrinking margins from new-hospital costs, depreciation and interest.
- Return on equity has dropped to 11% last year, from 15% over 3 years and 18% over 5 years. That means lower returns on a growing capital base.
- The stock trades at a high multiple of book value: P/B of 8.97, or 13.9x book by the cons-list measure. That leaves little room for error if the ramp-up of new hospitals takes longer than expected.
- The company may be capitalising interest cost. If so, reported profit may look better than it would under full expensing, and the -43% TTM profit decline could be understated.
- Promoter holding fell by 1.62% over the last quarter. Investors may read this as a negative signal on insider conviction.
- Stock returns have slowed to 7% over 1 year, from 26% CAGR over 3 and 5 years. The market may already be reacting to weaker earnings momentum.
- The company pays no dividend (0% yield) despite reporting repeated profits, so shareholders rely entirely on capital gains.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Q1 FY27 net profit roughly halves Sep 10
Q1 FY27 consolidated net profit fell to ₹37 crore from ₹85 crore YoY, one report says. Another report cites ₹41.5 crore vs ₹78.6 crore, down 47.2%. Both blame finance and operating costs at newly opened hospitals.
- Promoters pledge 6.66% stake Sep 23
Promoters Bhaskara Rao Bollineni and Bollineni Seenaiah Naidu pledged 2.80 crore shares, a 6.66% stake, to Catalyst Trusteeship on Sep 18, 2026. Promoter pledges can raise governance and overhang concerns if they grow.
- EBITDA margin compression from expansion Sep 3
Q1 FY27 EBITDA margin fell to 18.9% from 22.1%, or to 20.1% from 22.7% per a separate report, because new hospitals are still ramping up. FY26 occupancy was only 51%.
- Stock down 6% in a month Sep 3
Before Investec's initiation, the stock had fallen 6% in a month, cutting its year-to-date gain to 25%.
- Asset-light Kakinada O&M deal Sep 10
KIMS signed an exclusive O&M agreement with Sarvottam Health Care to run a 183-bed hospital in Kakinada, Andhra Pradesh. It earns a 9% fee on net revenue for 5 years, extendable by 5 more, with no upfront capex. The stock closed at ₹774 on BSE, though the reported 9.2% gain doesn't match the stated ₹1.20 rise, which works out to about 0.2%.
- Investec initiates Buy, ₹1,000 target Sep 3
Investec started coverage with a Buy rating and a ₹1,000 target, 32.7% upside, projecting FY26-29 revenue and EBITDA CAGR of 25% and 33%. It sees 51% occupancy and 21% EBITDAM as near cyclical lows. The stock rose 2.3% to ₹770.7.
- Strong Q1 FY27 revenue growth Sep 10
Operating revenue grew 35.3% YoY to ₹1,179.5 crore from ₹871.6 crore. Total consolidated revenue was ₹1,196 crore, up 36.1%.
- QIP proceeds cut debt Sep 10
KIMS used ₹1,500 crore of QIP proceeds to bring total debt down to about ₹2,400 crore. That should ease the finance costs that are weighing on profits.
- Near-unanimous analyst Buy consensus Sep 3
19 of the 20 analysts covering KIMS rate it Buy. Only one has a Sell rating.
- J.P. Morgan conference investor meet Sep 15
KIMS will meet analysts and institutional investors in Mumbai on Sep 21, 2026, at the J.P. Morgan India Conference.
- Emkay-hosted Mahadevpura facility meet Sep 7
KIMS hosted an institutional investor meeting at its Mahadevpura facility on Sep 10, 2026, organized by Emkay Global.
TL;DR: KIMS is growing revenue at about 35% YoY as its new hospitals in Maharashtra, Karnataka and Kerala ramp up. The asset-light Kakinada deal and QIP-funded debt cut, down to about ₹2,400 crore, address worries about capex and the balance sheet. The main risks are a near-halving of Q1 FY27 net profit, margins about 3 points lower, 51% occupancy and a new 6.66% promoter pledge. Sources also disagree on some figures, including Q1 profit (₹37 crore vs ₹41.5 crore) and the Sep 10 share-price move. Analysts are strongly positive, and the trend should improve if occupancy and margins recover from what Investec calls cyclical lows over FY27-29.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 606 | 652 | 606 | 634 | 688 | 777 | 772 | 797 | 872 | 961 | 998 | 1,075 | 1,180 |
| Expenses | 449 | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 | 799 | 868 | 956 |
| Operating Profit | 157 | 177 | 147 | 159 | 179 | 218 | 187 | 198 | 193 | 204 | 199 | 206 | 223 |
| OPM % | 26% | 27% | 24% | 25% | 26% | 28% | 24% | 25% | 22% | 21% | 20% | 19% | 19% |
| Other Income | 3 | 3 | 3 | 4 | 5 | 5 | 18 | 15 | 7 | 4 | 5 | 1 | 17 |
| Interest | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 | 57 | 68 | 83 |
| Depreciation | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 | 79 | 85 | 101 |
| PBT | 119 | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 | 97 | 69 | 55 | 57 |
| Tax % | 27% | 27% | 25% | 28% | 25% | 26% | 31% | 21% | 25% | 26% | 24% | 40% | 34% |
| Net Profit | 87 | 101 | 77 | 72 | 95 | 121 | 92 | 106 | 85 | 72 | 52 | 33 | 37 |
| EPS in Rs | 2.02 | 2.3 | 1.8 | 1.64 | 2.16 | 2.68 | 2.22 | 2.54 | 1.96 | 1.67 | 1.33 | 1.06 | 0.99 |
Profit & Loss
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 567 | 664 | 918 | 1,123 | 1,330 | 1,651 | 2,198 | 2,498 | 3,035 | 3,905 | 4,212 |
| Expenses | 403 | 450 | 593 | 833 | 872 | 953 | 1,126 | 1,587 | 1,850 | 2,242 | 3,090 | 3,380 |
| Operating Profit | 109 | 118 | 71 | 85 | 251 | 377 | 524 | 611 | 648 | 793 | 815 | 833 |
| OPM % | 21% | 21% | 11% | 9% | 22% | 28% | 32% | 28% | 26% | 26% | 21% | 20% |
| Other Income | 5 | 3 | 37 | 6 | 5 | 9 | 27 | 41 | 13 | 43 | 17 | 28 |
| Interest | 37 | 32 | 88 | 49 | 44 | 37 | 22 | 37 | 55 | 100 | 215 | 253 |
| Depreciation | 36 | 35 | 40 | 56 | 71 | 70 | 73 | 129 | 147 | 177 | 283 | 331 |
| PBT | 41 | 53 | -20 | -15 | 141 | 279 | 457 | 485 | 460 | 558 | 334 | 277 |
| Tax % | 32% | 37% | 126% | 223% | 18% | 26% | 25% | 25% | 27% | 26% | 28% | — |
| Net Profit | 28 | 33 | -46 | -49 | 115 | 205 | 344 | 366 | 336 | 415 | 242 | 194 |
| EPS in Rs | 0.76 | 0.91 | -1.32 | -1.28 | 3.2 | 5.19 | 8.32 | 8.41 | 7.75 | 9.61 | 6.03 | 5.05 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 72 | 50 | 74 | 74 | 78 | 80 | 80 | 80 | 80 | 80 |
| Reserves | 193 | 255 | -209 | 466 | 524 | 786 | 1,307 | 1,590 | 1,748 | 2,058 | 2,167 |
| Borrowings | 256 | 280 | 753 | 336 | 369 | 316 | 257 | 678 | 1,355 | 2,562 | 4,253 |
| Other Liabilities | 146 | 167 | 359 | 237 | 228 | 253 | 260 | 553 | 636 | 990 | 1,190 |
| Total Liabilities | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,901 | 3,820 | 5,689 | 7,691 |
| Fixed Assets | 515 | 518 | 755 | 863 | 916 | 931 | 1,005 | 1,766 | 2,434 | 3,348 | 5,710 |
| CWIP | 2 | 64 | 0 | 0 | 2 | 9 | 21 | 477 | 600 | 1,214 | 606 |
| Investments | 11 | 14 | 0 | 0 | 0 | 0 | 332 | 68 | 157 | 99 | 103 |
| Other Assets | 137 | 177 | 199 | 250 | 276 | 493 | 546 | 590 | 629 | 1,028 | 1,271 |
| Total Assets | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,901 | 3,820 | 5,689 | 7,691 |
Cash Flow
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 95 | 82 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 | 511 |
| Investing | -41 | -100 | -64 | -110 | -125 | -354 | -412 | -416 | -753 | -1,116 | -1,452 |
| Financing | -65 | 24 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 | 940 |
| Net Cash Flow | -11 | 5 | 3 | -3 | 32 | 12 | -26 | 36 | -15 | 9 | -1 |
| Free Cash Flow | 61 | -18 | 49 | 57 | 150 | 262 | 154 | -140 | -125 | -380 | -902 |
| CFO/OP | 88 | 80 | 192 | 195 | 102 | 104 | 86 | 87 | 102 | 91 | 81 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 59 | 59 | 49 | 43 | 30 | 28 | 42 | 43 | 48 | 52 |
| Inventory Days | 36 | 43 | 46 | 47 | 44 | 30 | 37 | — | — | — | — |
| Days Payable | 194 | 207 | 215 | 181 | 177 | 167 | 133 | — | — | — | — |
| Cash Conversion Cycle | -111 | -105 | -110 | -85 | -91 | -106 | -67 | 42 | 43 | 48 | 52 |
| Working Capital Days | 11 | 26 | -333 | -15 | -15 | -31 | -3 | 8 | -5 | -29 | -37 |
| ROCE % | — | 15% | 11% | 5% | 20% | 29% | 34% | 24% | 17% | 15% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Krishna Institute of Medical Sciences insights
62 extracted metrics + investor summaries across FY05–FY27.
Documents
Frequently Asked Questions about Krishna Institute of Medical Sciences
What does Krishna Institute of Medical Sciences Ltd do?
Where is Krishna Institute of Medical Sciences Ltd (KIMS) listed?
Which sector does Krishna Institute of Medical Sciences Ltd belong to?
What is the market capitalisation of Krishna Institute of Medical Sciences Ltd?
What is the PE ratio of Krishna Institute of Medical Sciences Ltd?
What is the 52-week high and low of Krishna Institute of Medical Sciences Ltd?
What is the Return on Equity (ROE) of Krishna Institute of Medical Sciences Ltd?
Company Information
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KIMS.md for Krishna Institute of Medical Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.